Pharmaceutical

EC grants orphan drug designation for Precigen’s PRGN-2012

The EC has granted orphan drug designation (ODD) for Precigen's PRGN-2012 aimed at treating recurrent respiratory papillomatosis (RRP).

Jan 17, 2024 - 18:00
EC grants orphan drug designation for Precigen’s PRGN-2012
The EC has granted orphan drug designation (ODD) for Precigen's PRGN-2012 aimed at treating recurrent respiratory papillomatosis (RRP).
Read the original article

Tags:

Previous Article

FDA approves Vertex’s gene-edited therapy for beta thalassemia

Next Article

Disco Pharmaceuticals Unveils Surfaceome Mapping for Enhanced Cancer Therapeutics

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: The biotech scorecard for the first quarter: 17 stock-moving events to watch

STAT+: The biotech scorecard for the first quarter: 17 ...

Jan 2, 2024

CMN-005 by CoImmune for Nodal Marginal Zone B-Cell Lymp...

Sep 10, 2024

STAT+: FDA official offers insights into whether gene therapy makers could use common manufacturing process

STAT+: FDA official offers insights into whether gene t...

May 19, 2023